Special Issue "Advances in Anticancer Drug Discovery"
Deadline for manuscript submissions: closed (31 January 2021).
Interests: drug discovery; virtual screening; molecular modelling; chemical space; density functional theory
Special Issues and Collections in MDPI journals
In some developed countries, cancer is now the main cause of death. Even though great progress has been made in the treatment of cancer, and practically some cancer types are curable, there is an acute need for much-improved therapies. In particular, with aging demographics more people will develop neoplastic diseases and, eventually, cancer. A further consideration is that elderly people are less able to tolerate aggressive surgery, radiation therapy, and/or cytotoxic drugs. Therefore, oncologists are often forced to make the difficult decision not to propose any intervention and can only offer palliative care. Therefore, the need for more benign anticancer therapies is acute.
In this Special Issue, we wish to focus on the area of drug discovery, design, and development, where new biological targets are being investigated and small molecules with potency against various cancer types are being developed, which in turn will lay the foundations for novel and more benign anticancer therapies.
Dr. Jóhannes Reynisson FRSC
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Molecules is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2000 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- Drug discovery
- Drug design
- Screening—high throughput
- and fragment-based
- Chemical space
- Structural activity relationship (SAR)
- Biochemical assays
- Biophysical assays
- Cell-based assays